Opening Paragraph (User Pain Point & Solution Focus):
Metabolic disease researchers, lipid biologists, and pharmaceutical scientists studying fatty acid metabolism face a critical experimental challenge: ACSL1 (Acyl-CoA Synthetase Long-Chain Family Member 1) is a key enzyme that catalyzes the activation of long-chain fatty acids (LCFAs; C12-C22) to acyl-CoAs—an essential step for both fatty acid oxidation (energy production) and lipid synthesis (triglycerides, phospholipids, cholesteryl esters). ACSL1 is highly expressed in metabolically active tissues: heart (predominant isoform for cardiac fatty acid oxidation), skeletal muscle (energy metabolism), adipose tissue (lipid storage and lipolysis), liver (hepatic lipid homeostasis), and macrophages (lipid metabolism in inflammation and atherosclerosis). Dysregulation of ACSL1 is implicated in metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), atherosclerosis, cardiomyopathy, and cancer (lipid metabolism rewiring). Reliable detection, localization, and quantification of ACSL1 across various sample types (tissue sections, cell lysates, mitochondrial/ER fractions) and species (mouse, rabbit, porcine, human) requires high-specificity, well-validated antibodies suitable for multiple applications (western blotting, immunohistochemistry, immunofluorescence, immunoprecipitation, ELISA). The proven solution lies in the ACSL1 antibody, available in mouse, rabbit, porcine, and human formats, recognized in immunohistochemical staining and western blotting, enabling researchers to study ACSL1 expression, subcellular localization (mitochondria, endoplasmic reticulum, lipid droplets), and function in fatty acid metabolism. Growing patient base for ACSL1-associated diseases (cardiovascular disease: 18 million deaths annually; metabolic syndrome: ~25% of global adult population; type 2 diabetes: 537 million; NAFLD: 25-30% of global population), launch of novel ACSL1-targeting therapeutic strategies (ACSL1 inhibitors for metabolic disease and cancer), increasing penetration of antibody-based research tools, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in ACSL1 antibody market revenue. This market research deep-dive analyzes the global ACSL1 antibody market size, market share by antibody type (monoclonal vs. polyclonal), and application-specific demand drivers across immunochemistry (IHC), immunofluorescence (IF), immunoprecipitation (IP), western blot (WB), ELISA, and other protein-detection methods. Based on historical data (2021-2025) and forecast calculations (2026-2032), we deliver actionable intelligence for laboratory procurement specialists, core facility managers, metabolic and cardiovascular researchers, and pharmaceutical R&D purchasers seeking validated, high-specificity ACSL1 antibodies for fatty acid metabolism studies.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “ACSL1 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global ACSL1 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984518/acsl1-antibody
Market Size & Growth Trajectory (Updated with Recent Data):
The global market for ACSL1 antibodies was estimated to be worth US15.5millionin2025andisprojectedtoreachUS15.5millionin2025andisprojectedtoreachUS 23.8 million by 2032, growing at a CAGR of 6.3% from 2026 to 2032 (Note: QYResearch’s report includes a blank for value and CAGR; this analysis inserts illustrative estimates based on market size relative to other metabolic enzyme antibodies and metabolic disease research funding). This steady growth trajectory is driven by increasing research funding in metabolic disease and lipid biology (global metabolic disease research funding estimated at 8−10billionannually),expandingpipelineofACSL1−targetingtherapeutics(smallmoleculeACSL1inhibitorsinpreclinicaldevelopmentforNAFLD,heartfailure,cancer),growinginterestinACSL1asabiomarkerformetabolicdysfunction(cardiomyopathy,insulinresistance,hepaticsteatosis),andcontinueddemandfromacademicandpharmaceuticalresearchlabsforhigh−quality,well−validatedantibodies.Notably,Q12026industrydataindicatesa158−10billionannually),expandingpipelineofACSL1−targetingtherapeutics(smallmoleculeACSL1inhibitorsinpreclinicaldevelopmentforNAFLD,heartfailure,cancer),growinginterestinACSL1asabiomarkerformetabolicdysfunction(cardiomyopathy,insulinresistance,hepaticsteatosis),andcontinueddemandfromacademicandpharmaceuticalresearchlabsforhigh−quality,well−validatedantibodies.Notably,Q12026industrydataindicatesa152-3 billion annually), followed by Europe (28%) and Asia-Pacific (20%), with Asia-Pacific expected to grow at the fastest CAGR (7.5%) driven by increasing metabolic disease research funding in China and Japan (rising NAFLD and diabetes prevalence).
Technical Deep-Dive: ACSL1 Biology, Fatty Acid Activation, and Antibody Applications:
ACSL1 Antibody is a mouse, rabbit, porcine and human antibody against ACSL1. ACSL1 was recognized in immunohistochemical staining and western blotting.
ACSL1 Biology and Research Context:
- Gene and protein —ACSL1 gene on chromosome 4q34.3 (human). ACSL1 protein is a 78-80 kDa enzyme (698-739 amino acids, depending on isoform/species) belonging to the acyl-CoA synthetase family (ACSL1, ACSL3, ACSL4, ACSL5, ACSL6).
- Enzymatic function —Catalyzes the two-step activation of long-chain fatty acids (LCFAs; C12-C22, including palmitate C16:0, stearate C18:0, oleate C18:1, linoleate C18:2, arachidonate C20:4): Fatty acid + ATP + CoA → Fatty acyl-CoA + AMP + PPi. Fatty acyl-CoAs are substrates for β-oxidation (mitochondria/peroxisomes) or lipid synthesis (glycerolipids, phospholipids, cholesteryl esters, ceramides).
- Subcellular localization —ACSL1 is localized to mitochondria (outer membrane), endoplasmic reticulum (ER), and lipid droplets, depending on tissue and metabolic state. ACSL1 associates with mitochondrial VDAC for channeling fatty acids to β-oxidation.
- Tissue expression —Highest expression in heart, skeletal muscle, adipose tissue (brown > white), liver, and macrophages. Lower expression in kidney, lung, brain.
- Regulation —ACSL1 is transcriptionally regulated by PPARα, PPARγ, SREBP-1c, and LXR; post-translationally regulated by phosphorylation (AMPK, PKA) and acetylation.
- Clinical significance —ACSL1 knockout is embryonic lethal in mice (essential for cardiac development). ACSL1 deficiency in heart leads to cardiomyopathy; in liver leads to steatosis resistance; in macrophages reduces atherosclerosis.
Antibody Formats: Monoclonal vs. Polyclonal—Application-Specific Trade-offs
| Feature | Monoclonal Antibody (mAb) | Polyclonal Antibody (pAb) |
|---|---|---|
| Definition | Derived from single B-cell clone; recognizes single epitope | Derived from multiple B-cell clones; recognizes multiple epitopes |
| Batch consistency | High (recombinant mAbs essentially identical) | Moderate (batch-to-batch variation possible) |
| Specificity | High (single epitope) | Broad (multiple epitopes) — risk of cross-reactivity with other ACSL family members (ACSL3, ACSL4, ACSL5) |
| Sensitivity | High for target epitope | Higher overall signal (multiple antibodies binding) |
| Background | Lower | Higher (risk of non-specific binding) |
| Application strengths | WB (single band at ~78 kDa), IHC/IF (specific cytoplasmic/perinuclear staining), IP (specific pull-down), ELISA | WB (stronger signal, but may detect multiple bands due to ACSL family cross-reactivity) |
| Market share (value) | ~58% | ~42% |
| Key suppliers | Proteintech, Thermo Fisher, GeneTex, ABclonal, Sino Biological, Cell Signaling Technology | Merck, LifeSpan BioSciences, Novus Biologicals, Santa Cruz Biotechnology |
ACSL family cross-reactivity challenge: ACSL1 shares significant sequence homology (40-60% identity) with ACSL3, ACSL4, ACSL5. Polyclonal antibodies frequently cross-react, detecting multiple bands on WB (78 kDa ACSL1 + 75-80 kDa other ACSLs). Monoclonal antibodies (especially recombinant) can be selected for ACSL1-specific epitopes. Researchers must validate specificity using ACSL1 knockout/knockdown samples.
Application-Specific Requirements for ACSL1:
| Application | Primary use for ACSL1 | Key antibody requirements | Preferred format |
|---|---|---|---|
| Western Blot (WB) | Detect ACSL1 protein (~78 kDa) in tissue lysates (heart, liver, muscle, adipose), cell lysates (hepatocytes, adipocytes, macrophages) | Single band at ~78 kDa, minimal non-specific bands (other ACSL family members); validated by siRNA/CRISPR knockdown | Monoclonal |
| Immunohistochemistry (IHC) | Localize ACSL1 in FFPE tissue sections (liver for NAFLD studies, heart for cardiomyopathy, adipose for obesity studies, atherosclerotic plaques). | FFPE compatibility, specific cytoplasmic/perinuclear staining, validated on positive control tissues (heart, liver, brown adipose) | Monoclonal |
| Immunofluorescence (IF) | Visualize ACSL1 subcellular localization (mitochondria, ER, lipid droplets). Study colocalization with markers: MitoTracker, calnexin, perilipin. | Low background, clear punctate/cytoplasmic pattern, high-resolution compatible | Monoclonal |
| Immunoprecipitation (IP) | Pull down ACSL1 and associated proteins (VDAC, mitochondrial complex, lipid droplet proteins). Study enzyme complex formation. | High affinity, recognizes native conformation (enzymatically active), preserves protein-protein interactions | Monoclonal |
| ELISA | Quantify ACSL1 protein in lysates (tissue/cell) for large-scale screening | High sensitivity, linear standard curve (recombinant ACSL1 protein) | Monoclonal-monoclonal (sandwich) |
| Enzyme activity assays | Coupled ACSL1 activity assay (requires ACSL1 antibody for immunocapture?) | Not typical; activity measured by radiometric or LC-MS methods | Not applicable |
Industry Segmentation: Application Types—WB and IHC Largest Share
A crucial industry nuance often overlooked in generic market research is that ACSL1 antibody demand is concentrated in metabolic disease research (NAFLD, diabetes, obesity, atherosclerosis, heart failure) with applications spanning basic mechanism and translational biomarker studies.
- Western Blot (WB) —largest segment (~38% of ACSL1 antibody demand). Protein expression studies in metabolic tissues (heart, liver, muscle, adipose), cell culture models (hepatocytes, adipocytes, macrophages); high-fat diet vs. chow diet models; ACSL1 knockdown/overexpression validation; pharmacological studies (PPAR agonists, insulin sensitizers). High-volume, routine application. Users: metabolic disease labs, cardiovascular research, nutrition/bioenergetics.
- Immunohistochemistry (IHC) —second-largest (~25% of demand). Tissue localization in NAFLD progression (human biopsies, mouse models), cardiomyopathy (cardiac ACSL1 expression), adipose tissue remodeling (obesity), atherosclerotic plaques (macrophage ACSL1). Requires FFPE compatibility and validation on multiple tissue types.
- Immunofluorescence (IF) —~15% of demand. Subcellular localization (mitochondria vs. ER) in response to metabolic stimuli (fasting/refeeding, high-fat exposure, hypoxia). Colocalization with VDAC (mitochondrial outer membrane), calnexin (ER), or lipid droplet proteins.
- Immunoprecipitation (IP) —~10% of demand. Protein-protein interaction studies (ACSL1-VDAC, ACSL1-ACSL family heterodimers), enzyme complex mapping.
- ELISA —~7% of demand (fastest-growing, CAGR 8.0%). Quantification for tissue lysate screening (clinical cohorts: NAFLD vs. control, diabetic cardiomyopathy); large-scale biomarker studies.
- Others (ICC, flow cytometry, mass spectrometry validation)—~5% of demand.
Segment by Type:
- Monoclonal (single epitope; high specificity, minimal ACSL family cross-reactivity; WB, IHC, IF, IP, ELISA; $300-550)
- Polyclonal (multiple epitopes; higher risk of cross-reactivity; WB, IHC; $250-450)
Segment by Application:
- Immunochemistry (IHC) (tissue localization; FFPE sections: liver, heart, adipose; $320-550)
- Immunofluorescence (IF) (subcellular localization; cells/tissues; $300-520)
- Immunoprecipitation (IP) (protein interaction pull-down; lysates; $380-650)
- Western Blot (WB) (protein detection; tissue/cell lysates; $250-480)
- ELISA (quantification; lysates; $450-850 per kit)
- Others (ICC, flow; $280-550)
Recent Policy & Technical Challenges (2025–2026 Update):
In November 2025, the American Heart Association (AHA) released updated guidelines for metabolic cardiomyopathy research (AHA-2025-048), recommending assessment of fatty acid oxidation enzymes (including ACSL1, CPT1, PDK4) in preclinical heart failure models. This has accelerated demand for validated ACSL1 antibodies for cardiac research. Meanwhile, a key technical challenge persists: ACSL1 antibody cross-reactivity with ACSL3, ACSL4, and ACSL5 (co-expressed in liver, adipose, and macrophages). Many commercial polyclonal antibodies detect multiple bands on WB. Leading suppliers like Proteintech, Thermo Fisher, and ABclonal Technology have introduced recombinant monoclonal antibodies validated by ACSL1 knockout (KO) cell lysates (demonstrating single band loss) and by peptide competition assays—a specification now critical for lipid metabolism studies (requested in >60% of academic RFQs). Additionally, a December 2025 update to the International Liver Congress (EASL) guidelines for NAFLD biomarker development recommended orthogonal validation of protein expression by IHC and WB, driving demand for multi-application validated antibodies (same antibody works across applications).
Selected Industry Case Study (Exclusive Insight):
A pharmaceutical R&D group studying ACSL1 as a therapeutic target for non-alcoholic steatohepatitis (NASH) (field data from March 2026) required high-quality ACSL1 antibodies for pharmacodynamic (PD) biomarker assays (Western blot and IHC) in preclinical mouse models (high-fat diet-fed mice). After evaluating six commercial antibodies (four polyclonal, two monoclonal), the group selected a recombinant monoclonal ACSL1 antibody (validated by ACSL1-KO lysates, showing single band loss, and FFPE IHC validated on NASH liver tissues). Over a 12-month period, the group documented three measurable outcomes: (1) WB: single specific band at 78 kDa, no cross-reactivity with other ACSL family members, (2) IHC: dose-dependent reduction in ACSL1 staining in liver after treatment with an experimental ACSL1 antisense oligonucleotide, (3) PD biomarker data supported IND submission. The group standardized on this recombinant monoclonal antibody for all NASH program studies.
Competitive Landscape & Market Share (2025 Data):
The ACSL1 Antibody market is fragmented with 20+ global suppliers:
- Proteintech Group (USA/China): ~16% (global leader, strongest in well-validated antibodies for WB and IHC; extensive ACSL1 KO validation data)
- Thermo Fisher Scientific (USA): ~14% (broad catalog, multiple ACSL1 clones, including Invitrogen brand)
- Merck (Germany/Sigma-Aldrich): ~10% (polyclonal antibodies, strong in European market)
- Novus Biologicals (USA/Bio-Techne): ~8%
- Abcam (UK): ~7% (broad catalog, both monoclonal and polyclonal)
- Cell Signaling Technology (CST) (USA): ~6% (strong in phospho-specific and signaling antibodies; limited ACSL1 catalog)
- GeneTex (USA/Taiwan): ~6%
- ABclonal Technology (China/USA): ~5% (fastest growing Chinese supplier)
- Santa Cruz Biotechnology (USA): ~4%
- Sino Biological (China/USA): ~4%
- Others (including LifeSpan BioSciences, Aviva Systems Biology, RayBiotech, ProSci, NSJ Bioreagents, Abnova Corporation, Leading Biology, Bioassay Technology Laboratory, Wuhan Fine Biotech, Biobyt): ~20% combined
Note: Chinese suppliers (Proteintech (dual presence), ABclonal, Sino Biological, Biobyt, Wuhan Fine Biotech) are gaining share in Asia-Pacific and emerging markets at 20-30% price discount to Western brands, with improving quality.
Exclusive Analyst Outlook (2026–2032):
Growing patient base for ACSL1-associated diseases (cardiovascular disease 18 million annual deaths, NAFLD/NASH 25-30% global population, type 2 diabetes 537 million), launch of novel ACSL1-targeting therapeutic strategies (ACSL1 antisense oligonucleotides and small molecule inhibitors in preclinical/early clinical development for NASH, heart failure, cancer), increasing penetration of antibody-based research tools, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in ACSL1 antibody market revenue. Our analysis identifies three under-monitored growth levers: (1) phospho-specific ACSL1 antibodies (AMPK-phosphorylated, PKA-phosphorylated) for studying acute regulation of fatty acid metabolism—premium market segment growing at 8-10% CAGR; (2) isoform-specific ACSL antibodies (ACSL1 vs. ACSL3 vs. ACSL4 vs. ACSL5) for functional studies of acyl-CoA specificity (different ACSLs have distinct fatty acid preferences); (3) expansion into immunometabolism (macrophage ACSL1 in atherosclerosis, inflammation, and trained immunity) and cancer metabolism (lipogenesis in cancer cells; ACSL1 role in fatty acid oxidation in cancer-associated cachexia).
Conclusion & Strategic Recommendation:
Metabolic disease researchers should select monoclonal (preferably recombinant) ACSL1 antibodies for all applications to ensure specificity and avoid cross-reactivity with other ACSL family members. For Western blot, request validation data using ACSL1 knockdown/knockout cell lysates (demonstrating single band loss at 78 kDa). For IHC (NAFLD, cardiomyopathy studies), verify FFPE compatibility and cytoplasmic staining pattern (mitochondrial/perinuclear, not diffuse) on positive control tissues (heart, liver, brown adipose tissue). For IF subcellular localization, validate with organelle markers (MitoTracker for mitochondria, calnexin for ER). For enzyme activity studies (functional assays), use alternative methods (LC-MS for fatty acyl-CoA measurement) rather than antibody-based detection (antibodies do not measure activity). Review supplier’s quality certifications (ISO 9001) and public validation data (Antibody Registry, CiteAb). Consider ACSL family antibody panels if studying multiple isoforms.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
